AbbVie is the 11th pharmaceutical maker to impose limits on 340B contract pharmacy.

Breaking News: AbbVie Becomes 11th Drug Maker to Restrict 340B Contract Pharmacy. Feds Appeal Rulings in Lilly, Novo Nordisk, and Sanofi Cases.

In Breaking, Federal, Judicial, Pharma IndustryDecember 29, 20211765 Views

AbbVie today announced conditions on 340B pricing when hospitals’ contract pharmacies dispense medicines to patients. The federal government has filed notices of appeal in Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics’ 340B contract pharmacy lawsuits.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga

Exact matches only

Search in title

Search in content

Search in excerpt

Hidden

*Sign up for news summaries and alerts from 340B Report